Pfizer and Celgene, as well as Osage University Partners and others, have backed a $38m series A round to help launch Arrakis Therapeutics.
US-based biopharmaceutical company Arrakis Therapeutics launched yesterday with a $38m series A round that featured pharmaceutical firms Pfizer and Celgene.
Canaan Partners led the round, with further participation from Osage University Partners, an investment fund focused on university spinouts, Advent Life Sciences and angel investor Henri Termeer.
Arrakis is working on discovery platforms for small-molecule drugs aimed at neurological, oncological and rare genetic disorders. The approach exploits the structure of folded RNAs within cells to design therapies that inhibit specific…
